C
10.71
-0.57 (-5.05%)
| Previous Close | 11.28 |
| Open | 11.44 |
| Volume | 1,234,457 |
| Avg. Volume (3M) | 950,368 |
| Market Cap | 1,426,400,640 |
| Price / Sales | 233.74 |
| Price / Book | 4.51 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.06 |
| Total Debt/Equity (MRQ) | 29.34% |
| Current Ratio (MRQ) | 9.25 |
| Operating Cash Flow (TTM) | -142.06 M |
| Levered Free Cash Flow (TTM) | -75.19 M |
| Return on Assets (TTM) | -26.82% |
| Return on Equity (TTM) | -73.93% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Centessa Pharmaceuticals plc | Bullish | Bullish |
AIStockmoo Score
0.6
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
|
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.38% |
| % Held by Institutions | 93.27% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Index Venture Life Associates Vi Ltd | 31 Dec 2024 | 9,961,789 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 38.00 (Piper Sandler, 254.81%) | Buy |
| Median | 29.00 (170.78%) | |
| Low | 27.00 (Morgan Stanley, 152.10%) | Buy |
| Average | 30.75 (187.12%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 14.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 08 May 2025 | 30.00 (180.11%) | Buy | 12.39 |
| Piper Sandler | 31 Mar 2025 | 38.00 (254.81%) | Buy | 14.38 |
| Guggenheim | 26 Mar 2025 | 28.00 (161.44%) | Buy | 14.54 |
| Morgan Stanley | 07 Mar 2025 | 27.00 (152.10%) | Buy | 16.23 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |